PCVX earnings date and last-quarter result: P/E -8.13. Updated 2026-07-23.
Vaxcyte (PCVX) Research Hub
Vaxcyte (PCVX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 59.97 USD (-0.76%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.13, market cap 8.15B. This hub links to the full technical, earnings and options research available for PCVX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 59.97 USD (-0.76%) |
| 52-week range | 47.48 USD – 90.75 USD |
| Trend regime | Range |
| 14-day RSI | 37.4 (Bearish) |
| Trailing P/E | -8.13 |
| Market cap | 8.15B |
| Dividend yield | 0.00% |
Available research for PCVX
Covered Call on PCVX: how it works, illustrative setup around the real 59.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PCVX: how it works, illustrative setup around the real 59.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PCVX: how it works, illustrative setup around the real 59.97 USD price, max profit/loss, breakeven and when to use it. Educational.
PCVX technical analysis: range, last 59.97 USD, RSI 37.4, 52w range 47.48 USD–90.75 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PCVX in?
Vaxcyte (PCVX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PCVX in an uptrend or downtrend?
As of 2026-10-26, PCVX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PCVX's trailing P/E ratio?
PCVX's trailing P/E is -8.13, with a market cap of 8.15B. See the earnings research page for full valuation detail.